Parvovirus B19 Associated Hepatitis

Parvovirus B19 Associated Hepatitis

Parvovirus B19 infection can present with myriads of clinical diseases and syndromes; liver manifestations and hepatitis are examples of them. Parvovirus B19 hepatitis associated aplastic anemia and its coinfection with other hepatotropic viruses are relatively underrecognized, and there is sufficie...

Full description

Bibliographic Details
Main Authors: Bihari, Chhagan, Rastogi, Archana, Saxena, Priyanka, Rangegowda, Devraj, Chowdhury, Ashok, Gupta, Nalini, Sarin, Shiv Kumar
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819764/
id pubmed-3819764
recordtype oai_dc
spelling pubmed-38197642013-11-14 Parvovirus B19 Associated Hepatitis Bihari, Chhagan Rastogi, Archana Saxena, Priyanka Rangegowda, Devraj Chowdhury, Ashok Gupta, Nalini Sarin, Shiv Kumar Review Article Parvovirus B19 infection can present with myriads of clinical diseases and syndromes; liver manifestations and hepatitis are examples of them. Parvovirus B19 hepatitis associated aplastic anemia and its coinfection with other hepatotropic viruses are relatively underrecognized, and there is sufficient evidence in the literature suggesting that B19 infections can cause a spectrum of liver diseases from elevation of transaminases to acute hepatitis to fulminant liver failure and even chronic hepatitis. It can also cause fatal macrophage activation syndrome and fibrosing cholestatic hepatitis. Parvovirus B19 is an erythrovirus that can only be replicate in pronormoblasts and hepatocytes, and other cells which have globosides and glycosphingolipids in their membrane can also be affected by direct virus injury due to nonstructural protein 1 persistence and indirectly by immune mediated injury. The virus infection is suspected in bone marrow aspiration in cases with sudden drop of hemoglobin and onset of transient aplastic anemia in immunosuppressed or immunocompetent patients and is confirmed either by IgM and IgG positive serology, PCR analysis, and in situ hybridization in biopsy specimens or by application of both. There is no specific treatment for parvovirus B19 related liver diseases, but triple therapy regimen may be effective consisting of immunoglobulin, dehydrohydrocortisone, and cyclosporine. Hindawi Publishing Corporation 2013 2013-10-22 /pmc/articles/PMC3819764/ /pubmed/24232179 http://dx.doi.org/10.1155/2013/472027 Text en Copyright © 2013 Chhagan Bihari et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Bihari, Chhagan
Rastogi, Archana
Saxena, Priyanka
Rangegowda, Devraj
Chowdhury, Ashok
Gupta, Nalini
Sarin, Shiv Kumar
spellingShingle Bihari, Chhagan
Rastogi, Archana
Saxena, Priyanka
Rangegowda, Devraj
Chowdhury, Ashok
Gupta, Nalini
Sarin, Shiv Kumar
Parvovirus B19 Associated Hepatitis
author_facet Bihari, Chhagan
Rastogi, Archana
Saxena, Priyanka
Rangegowda, Devraj
Chowdhury, Ashok
Gupta, Nalini
Sarin, Shiv Kumar
author_sort Bihari, Chhagan
title Parvovirus B19 Associated Hepatitis
title_short Parvovirus B19 Associated Hepatitis
title_full Parvovirus B19 Associated Hepatitis
title_fullStr Parvovirus B19 Associated Hepatitis
title_full_unstemmed Parvovirus B19 Associated Hepatitis
title_sort parvovirus b19 associated hepatitis
description Parvovirus B19 infection can present with myriads of clinical diseases and syndromes; liver manifestations and hepatitis are examples of them. Parvovirus B19 hepatitis associated aplastic anemia and its coinfection with other hepatotropic viruses are relatively underrecognized, and there is sufficient evidence in the literature suggesting that B19 infections can cause a spectrum of liver diseases from elevation of transaminases to acute hepatitis to fulminant liver failure and even chronic hepatitis. It can also cause fatal macrophage activation syndrome and fibrosing cholestatic hepatitis. Parvovirus B19 is an erythrovirus that can only be replicate in pronormoblasts and hepatocytes, and other cells which have globosides and glycosphingolipids in their membrane can also be affected by direct virus injury due to nonstructural protein 1 persistence and indirectly by immune mediated injury. The virus infection is suspected in bone marrow aspiration in cases with sudden drop of hemoglobin and onset of transient aplastic anemia in immunosuppressed or immunocompetent patients and is confirmed either by IgM and IgG positive serology, PCR analysis, and in situ hybridization in biopsy specimens or by application of both. There is no specific treatment for parvovirus B19 related liver diseases, but triple therapy regimen may be effective consisting of immunoglobulin, dehydrohydrocortisone, and cyclosporine.
publisher Hindawi Publishing Corporation
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819764/
_version_ 1612024066488664064

Similar Items